What's new

[Cyprus Times] Inclusion of new drugs in the GESY for the treatment of type 2 diabetes mellitus

xapiaaaa750.jpg

Inclusion of new drugs in the GESY for the treatment of type 2 diabetes mellitus See the drugs in detail

The Health Insurance Organisation (HIO) wishes to inform beneficiaries that as of Friday, July 15, 2022, the following drugs in the class of SGLT-2 inhibitors will be available from the SHI for patients with type 2 diabetes mellitus:

FORXIGA TABLET 10MG
INVOKANA TABLET 100MG and INVOKANA TABLET 300MG
JARDIANCE TABLET 10MG and JARDIANCE TABLET 25MG
STEGLATRO TABLET 15MG and STEGLATRO TABLET 5MG
SYNJARDY TABLET 12.5MG/1000MG, SYNJARDY TABLET 12.5MG/850MG, SYNJARDY TABLET 5MG/1000MG and SYNJARDY TABLET 5MG/850MG
VOKANAMET TABLET 150MG/1000MG, VOKANAMET TABLET 150MG/850MG, VOKANAMET TABLET 50MG/1000MG, VOKANAMET TABLET 50MG/850MG
XIGDUO TABLET 5MG/1000MG, XIGDUO TABLET 5MG/850MG

Prescribing through the GHS IT system of the above pharmaceutical products will be possible if:

made by Adult Personal Physicians, Geriatricians and Endocrinologists[/B]

beneficiaries meet the protocol criteria.
Beneficiaries are requested to contact their treating physician in order to find out whether they meet these criteria.


Contents of this article including associated images are belongs Cyprus Times
Views & opinions expressed are those of the author and/or Cyprus Times

Source[/URL]
Source

 
Back
Top